Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Down 1.3 %

PULM stock opened at $6.04 on Tuesday. The company has a 50 day moving average of $2.73 and a two-hundred day moving average of $2.27. The company has a market cap of $22.05 million, a price-to-earnings ratio of -2.29 and a beta of 0.99. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.